Saturday 17 October 2026
Export ARDX’s income statement to Excel — free account
Ardelyx, Inc.
ARDX Healthcare Biotechnology
Ardelyx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $407.3 million, up 22.1% from fiscal 2024. In the quarter to June 2026, revenue grew 23.8%, EPS grew 12.5%, free cash flow grew 75.3% and total debt rose 25.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
3.09
0.18
−5.50%
Follow ARDX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.35 | 3.45 | 3.44 | 2.81 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
3,651.82 | 67.07 | (45.68) | (197.71) | |
P/B ratio |
8.64 | 8.42 | 9.91 | 8.49 | |
Price to Tangible BV |
8.64 | 8.42 | 9.91 | 8.49 | |
EV/Sales |
3.31 | 3.36 | 3.43 | 2.80 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(24.60) | (32.26) | (40.40) | (72.87) | |
EV/FCF |
(23.84) | (31.16) | (39.07) | (70.44) | |
Quick Ratio |
3.83 | 3.80 | 2.93 | 2.89 | |
Current Ratio |
4.41 | 4.31 | 3.49 | 3.34 | |
Net Debt/EBITDA |
(7.28) | (10.27) | 1.08 | 2.54 | |
Debt/Assets |
41.58% | 40.44% | 40.34% | 43.73% | |
Debt/Equity |
1.31 | 1.21 | 1.37 | 1.69 | |
Asset Turnover |
0.93 | 0.87 | 0.94 | 0.86 | |
Operating CF/Net income |
(0.38) | (51.48) | 0.86 | 0.38 | |
Capex/Depreciation |
(0.17) | (0.39) | (0.08) | (0.02) | |
Interest Coverage |
0.58 | 0.67 | (4.74) | (2.00) | |
Research and Development Expense of Revenue |
16.38% | 18.25% | 21.37% | 21.59% | |
Selling, General and Administrative Expense of Revenue |
75.78% | 69.01% | 108.25% | 83.92% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
11.55% | 9.94% | 14.99% | 12.67% | |
Graham Net Nets |
0.03 | 0.03 | 0.02 | 0.01 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.25%) | (4.36%) | (3.91%) | (4.39%) | |
Free Cash Flow Yield |
(4.15%) | (3.13%) | (2.55%) | (1.42%) | |
Revenue per Share |
0.46 | 0.52 | 0.38 | 0.49 | |
Operating CF per Share |
0.00 | 0.09 | (0.13) | (0.03) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.09 | (0.13) | (0.03) | |
Cash per Share |
1.00 | 1.10 | 0.97 | 1.14 | |
Shareholders Equity per Share |
0.64 | 0.69 | 0.60 | 0.60 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.64 | 0.69 | 0.60 | 0.60 | |
Free Cash Flow |
0.21 | 20.59 | (32.31) | (6.41) | |
Working Capital |
284.60 | 293.71 | 272.30 | 309.71 | |
Capital Expenditures |
(0.16) | (0.36) | (0.07) | (0.01) | |
Net Current Asset Value |
36.10 | 47.66 | 25.99 | 15.05 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
64.90 | 64.78 | 64.65 | 81.45 | |
Average Payables |
17.11 | 17.62 | 20.96 | 30.05 | |
Average Inventory |
18.28 | 19.45 | 23.26 | 24.07 | |
Average Assets |
427.02 | 468.68 | 457.35 | 521.33 | |
Average Common Equity |
156.29 | 170.12 | 147.15 | 144.27 |
Columns are period end dates